Were Analysts Bearish BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) This Week?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Logo
Investors sentiment decreased to 1.13 in Q2 2019. Its down 0.20, from 1.33 in 2019Q1. It is negative, as 31 investors sold BioMarin Pharmaceutical Inc. shares while 128 reduced holdings. 57 funds opened positions while 122 raised stakes. 172.04 million shares or 22.86% less from 223.01 million shares in 2019Q1 were reported.
Ontario – Canada-based Toronto Dominion Bank has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Pictet Asset Management Ltd owns 1.35 million shares for 0.25% of their portfolio. Assetmark has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 89 shares. Van Eck Assocs Corporation reported 0.08% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Aviva Public Ltd Company holds 0.04% or 65,295 shares in its portfolio. Parametric Associate Ltd reported 0.02% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Rmb Cap Management Limited Liability Company stated it has 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Moreover, Cornerstone has 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 1,163 shares. Efg Asset Mgmt (Americas) Corporation has invested 0.84% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Price T Rowe Md has 0.03% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 2.30 million shares. 916,313 are held by Neuberger Berman Grp Inc Ltd Com. Meeder Asset Mngmt stated it has 235 shares. Cibc Asset holds 0.01% or 17,021 shares. Appleton Ptnrs Ma holds 0.07% or 6,410 shares in its portfolio. Paloma Prtn Mgmt holds 0.01% or 3,744 shares in its portfolio.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 2 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioMarin Pharmaceutical has $12800 highest and $110 lowest target. $119’s average target is 63.80% above currents $72.65 stock price. BioMarin Pharmaceutical had 3 analyst reports since March 22, 2019 according to SRatingsIntel. The stock has “Outperform” rating by Wedbush on Friday, April 26. The rating was maintained by Raymond James on Tuesday, April 9 with “Outperform”. Below is a list of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) latest ratings and price target changes.

26/04/2019 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $127.0000 New Target: $128.0000 Maintain
09/04/2019 Broker: Raymond James Rating: Outperform New Target: $110 Maintain
22/03/2019 Broker: BidaskScore Rating: Sell Downgrade

The stock decreased 0.21% or $0.15 during the last trading session, reaching $72.65. About 966,431 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 20.19% since September 13, 2018 and is downtrending. It has underperformed by 20.19% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $13.04 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Seekingalpha.com which released: “BioMarin Q2 miss pressures shares, down 3% after hours – Seeking Alpha” on August 01, 2019, also Nasdaq.com with their article: “BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat – Nasdaq” published on April 26, 2019, Finance.Yahoo.com published: “BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) Shift From Loss To Profit – Yahoo Finance” on July 10, 2019. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Finance.Yahoo.com and their article: “Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit? – Yahoo Finance” published on June 10, 2019 as well as Finance.Yahoo.com‘s news article titled: “Read This Before Buying BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares – Yahoo Finance” with publication date: May 10, 2019.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.